CAS: 42346-68-9; 1-Methyl-5-Oxopyrrolidine-3-Carboxylic Acid

相似化合物

5733-86-8 428518-42-7 59857-86-2

上下游产品

CAS号97-65-4 衣康酸 | CAS号74-89-5 氨基甲烷 | CAS号59857-86-2 1-甲基-2-氧代吡咯烷-4-甲酸甲酯 | CAS号617-52-7 衣康酸二甲酯 | CAS号59857-86-2 1-甲基-2-氧代吡咯烷-4-甲酸甲酯 | CAS号19597-07-0 1,3-二甲基吡咯烷-2-酮 | CAS号15542-96-8 1,3-dimethylpyr... | CAS号2555-04-6 1,4-二甲基-2-吡咯烷酮 | CAS号59887-20-6 4-(羟基甲基)-1-甲基吡咯烷-2-酮

📜1-甲基-5-氧代吡咯烷-3-羧酸甲酯置于sodium Hydroxide体系中,用 甲醇,水 作为反应溶剂,化学反应 24.0H,以91%的收率获得产物1-甲基-2-氧代吡咯烷-4-甲酸
参考文献:Synthetic Approaches To 10-Azaprostaglandins
标题:Synthetic Approaches To 10-Azaprostaglandins
摘要:
DOI:10.1021/jo01293A010

专利信息

专利号:US-5879690-A
优先权日:1995-09-07
标题:Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
发明人：PERRICONE NICHOLAS V
摘要:Compositions for the topical treatment of sagging subcutaneous muscle and overlying cutaneous tissue contain an active ingredient exhibiting or producing catecholamine activity such as catecholamines and/or related compounds in a dermatologically acceptable carrier that contains at least one percutaneous penetration enhancer. Examplary catecholamines include adrenaline, norepinepherine, dopamine and their precursors; catecholamine precursors such as tyrosine and phenylalanine are preferred. Many embodiments, particularly those employing tyrosine and/or phenylalanine as a catecholamine precursor, further contain a neurotransmitter synthesis enhancer such as dimethylaminoethanol, and other co-factors such as vitamin B 6 and pantothenic acid or calcium pantothenate are included in the composition to enhance the action of the active ingredients. Other compounds that scavenge free radicals and antioxidants may also be added.

专利号:US-7632519-B2
优先权日:2005-04-25
标 题:TRPV1 agonist compounds, formulations, prodrugs, methods for using the same
发明人：JAMIESON GENE CURTIS; MUHAMMAD NAWEED; BLEY KEITH R
权利人:NEUROGESX INC
摘要:Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.